SG11201706727XA - Methods, compositions, and kits for treatment of cancer - Google Patents
Methods, compositions, and kits for treatment of cancerInfo
- Publication number
- SG11201706727XA SG11201706727XA SG11201706727XA SG11201706727XA SG11201706727XA SG 11201706727X A SG11201706727X A SG 11201706727XA SG 11201706727X A SG11201706727X A SG 11201706727XA SG 11201706727X A SG11201706727X A SG 11201706727XA SG 11201706727X A SG11201706727X A SG 11201706727XA
- Authority
- SG
- Singapore
- Prior art keywords
- kits
- cancer
- compositions
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562118350P | 2015-02-19 | 2015-02-19 | |
| US201562150235P | 2015-04-20 | 2015-04-20 | |
| PCT/US2016/018634 WO2016134234A1 (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706727XA true SG11201706727XA (en) | 2017-09-28 |
Family
ID=56689191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706727XA SG11201706727XA (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for treatment of cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160243228A1 (en) |
| EP (1) | EP3258966A4 (en) |
| JP (2) | JP6774421B2 (en) |
| KR (1) | KR20170137717A (en) |
| CN (1) | CN107635583A (en) |
| AU (2) | AU2016219917B2 (en) |
| BR (1) | BR112017017700A2 (en) |
| CA (1) | CA2976638A1 (en) |
| IL (1) | IL253979B (en) |
| MX (1) | MX2017010595A (en) |
| SG (1) | SG11201706727XA (en) |
| WO (1) | WO2016134234A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI507205B (en) | 2009-03-25 | 2015-11-11 | Genentech Inc | Anti-fgfr3 antibodies and methods using same |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
| AU2015238301B2 (en) | 2014-03-26 | 2020-06-25 | Astex Therapeutics Ltd | Combinations |
| DK3122359T3 (en) | 2014-03-26 | 2021-03-08 | Astex Therapeutics Ltd | COMBINATIONS OF AN FGFR INHIBITOR AND AN IGF1R INHIBITOR |
| JOP20200201A1 (en) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
| US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| AU2016328692B2 (en) | 2015-09-23 | 2021-03-11 | Janssen Pharmaceutica Nv | New compounds |
| MX2018003564A (en) | 2015-09-23 | 2018-06-18 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer. |
| AU2018215794A1 (en) * | 2017-02-06 | 2019-07-25 | Fusion Pharmaceuticals Inc. | Methods, compositions, and kits for treatment of cancer |
| CN108440673B (en) * | 2018-04-08 | 2021-08-17 | 海南医学院 | Fc fusion protein PD1/FGFR1 and application thereof |
| CA3131880A1 (en) * | 2019-03-01 | 2020-09-10 | Fusion Pharmaceuticals Inc. | Methods and compositions for treating cancer |
| US20200277387A1 (en) * | 2019-03-01 | 2020-09-03 | Rainier Therapeutics, Inc. | Methods and compositions for treating cancer |
| CN114466662A (en) * | 2019-09-26 | 2022-05-10 | 詹森药业有限公司 | Use of FGFR inhibitors in cancers with genetically altered FGFR to enhance patient response to immune checkpoint inhibitors in a sequential therapy setting |
| EP4200019A1 (en) | 2020-08-21 | 2023-06-28 | Genzyme Corporation | Fgfr3 antibodies and methods of use |
| JPWO2022092085A1 (en) * | 2020-10-28 | 2022-05-05 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR073770A1 (en) * | 2008-10-20 | 2010-12-01 | Imclone Llc | ISOLATED ANTIBODY THAT LINKS SPECIFICALLY WITH, AND INDUCES THE DEGRADATION OF THE RECEPTOR-3 OF THE HUMAN FIBROBLAST GROWTH FACTOR (FGFR-3), FGFR-3 HUMAN LINK FRAGMENT OF THE SAME, PHARMACEUTICAL COMPOSITION AND PRODUCT COMPOSITION |
| TWI507205B (en) * | 2009-03-25 | 2015-11-11 | Genentech Inc | Anti-fgfr3 antibodies and methods using same |
| WO2012088266A2 (en) * | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| UY34887A (en) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
| CN104487087A (en) * | 2012-07-27 | 2015-04-01 | 基因泰克公司 | Methods of treating FGFR3 related conditions |
| BR112016000853A2 (en) * | 2013-07-16 | 2017-12-12 | Genentech Inc | methods for treating or delaying, reducing or inhibiting cancer relapse or progression and the progression of an immune-related disease in an individual, to increase, improve or stimulate an immune response or function in an individual and kit. |
-
2016
- 2016-02-19 SG SG11201706727XA patent/SG11201706727XA/en unknown
- 2016-02-19 CA CA2976638A patent/CA2976638A1/en active Pending
- 2016-02-19 BR BR112017017700A patent/BR112017017700A2/en active Search and Examination
- 2016-02-19 EP EP16753128.4A patent/EP3258966A4/en not_active Withdrawn
- 2016-02-19 JP JP2017544657A patent/JP6774421B2/en active Active
- 2016-02-19 MX MX2017010595A patent/MX2017010595A/en unknown
- 2016-02-19 US US15/048,030 patent/US20160243228A1/en not_active Abandoned
- 2016-02-19 WO PCT/US2016/018634 patent/WO2016134234A1/en active Application Filing
- 2016-02-19 CN CN201680022780.7A patent/CN107635583A/en active Pending
- 2016-02-19 AU AU2016219917A patent/AU2016219917B2/en active Active
- 2016-02-19 KR KR1020177025882A patent/KR20170137717A/en not_active Application Discontinuation
-
2017
- 2017-08-14 IL IL253979A patent/IL253979B/en active IP Right Grant
-
2020
- 2020-10-02 JP JP2020167443A patent/JP7122357B2/en active Active
-
2022
- 2022-01-13 AU AU2022200196A patent/AU2022200196A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016219917B2 (en) | 2021-12-16 |
| EP3258966A4 (en) | 2018-07-25 |
| EP3258966A1 (en) | 2017-12-27 |
| IL253979A0 (en) | 2017-10-31 |
| JP2018507220A (en) | 2018-03-15 |
| JP6774421B2 (en) | 2020-10-21 |
| AU2016219917A1 (en) | 2017-09-07 |
| CA2976638A1 (en) | 2016-08-25 |
| MX2017010595A (en) | 2018-11-12 |
| BR112017017700A2 (en) | 2018-07-31 |
| IL253979B (en) | 2021-06-30 |
| JP2021020909A (en) | 2021-02-18 |
| WO2016134234A1 (en) | 2016-08-25 |
| AU2022200196A1 (en) | 2022-02-10 |
| KR20170137717A (en) | 2017-12-13 |
| CN107635583A (en) | 2018-01-26 |
| JP7122357B2 (en) | 2022-08-19 |
| US20160243228A1 (en) | 2016-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258955A (en) | Compositions and methods for treatment of cancer | |
| IL253979B (en) | Methods, compositions, and kits for treatment of cancer | |
| IL267247B (en) | Compositions and methods for treating cancer | |
| HK1251408A1 (en) | Methods of treating cancer | |
| IL304820A (en) | Compositions and methods for treating cancer | |
| IL266053A (en) | Compositions and methods for treating ezh2-mediated cancer | |
| EP3393475A4 (en) | Methods of treating cancer | |
| EP3377516A4 (en) | Methods and compositions for treating cancer | |
| EP3166640A4 (en) | Combination therapy compositions and methods for treating cancers | |
| HK1247931A1 (en) | Compositions and methods for diagnosis and treatment of cancer | |
| EP3200815A4 (en) | Methods and compositions for treating cancer | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| EP3353204A4 (en) | Methods and compositions for treatment of cancer | |
| EP3347025A4 (en) | Methods and compositions for cancer treatment | |
| IL268163A (en) | Methods, compositions, and kits for treatment of cancer | |
| EP3325006A4 (en) | Methods of treating cd166-expressing cancer | |
| EP3328372A4 (en) | Compositions and methods of treating cancer | |
| SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
| EP3154544A4 (en) | Compositions and methods for treating cancers | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| EP3185910A4 (en) | Methods and compositions for the treatment of cancer | |
| EP3154952A4 (en) | Methods and compositions for treatment of her-positive cancers | |
| EP3268028A4 (en) | Compositions and methods for treating cancer | |
| HK1250958A1 (en) | Compositions and methods for treating cancer | |
| EP3160591A4 (en) | Compositions and methods for treating cancer |